IXHL
Incannex Healthcare, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$2.76
−2.13%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 66.6K | — | 86.0K | 12.0K | — |
| Cost of Revenue | 179.8K | 240.0K | 246.0K | 103.0K | — |
| Gross Profit | (128.4K) | (240.0K) | (160.0K) | 12.0K | — |
| Operating Expenses | |||||
| R&D Expense | 13.7M | 5.2M | 10.7M | 19.3M | 9.5M |
| SG&A Expense | 25.4M | 17.8M | 13.1M | 25.6M | 11.9M |
| General & Admin Expense | 25.1M | 17.8M | 12.7M | 24.0M | 10.0M |
| Selling & Marketing Expense | 287.6K | — | 390.0K | 1.6M | 1.9M |
| Other Expenses | (233.0K) | (240.0K) | (246.0K) | (14.8M) | (895.5K) |
| Total Operating Expenses | 38.9M | 22.8M | 23.6M | 30.1M | 20.5M |
| Cost and Expenses | 45.9M | 23.0M | 23.9M | 30.1M | 20.5M |
| Operating Income (EBIT) | (39.0M) | (23.0M) | (23.8M) | (30.0M) | (20.5M) |
| Non-Operating | |||||
| Interest Income | 61.0K | 21.0K | 62.0K | 308.4K | 362.7K |
| Interest Expense | 132.0K | — | 303.0K | — | — |
| Net Interest Income | (71.0K) | 21.0K | (241.0K) | 308.4K | 362.7K |
| Other Non-Op Income/Expense | (26.7M) | (933.0K) | (24.9M) | 178.0K | (52.9M) |
| Non-Operating Income (excl Interest) | (4.1M) | — | — | — | — |
| EBT (Pre-Tax Income) | (72.5M) | (24.0M) | (48.6M) | (18.4M) | (73.5M) |
| Income Tax Expense | — | (4.7M) | (1.8M) | 30.0K | — |
| Bottom Line | |||||
| Net Income | (52.3M) | (19.3M) | (46.9M) | (18.5M) | (73.5M) |
| Earnings from Cont. Ops | (52.3M) | (19.3M) | (46.9M) | (18.5M) | (73.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (58.8M) | (19.3M) | (46.9M) | (18.5M) | (73.5M) |
| Per Share | |||||
| Basic EPS | ($2.16) | ($1.66) | ($40.80) | ($3.42) | ($14.31) |
| Diluted EPS | ($2.16) | ($1.66) | ($40.80) | ($3.42) | ($14.31) |
| Revenue Per Share | $0.01 | $0.00 | $0.07 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 12.3M | 11.7M | 1.1M | 5.4M | 5.1M |
| Diluted Shares Outstanding | 12.3M | 11.7M | 1.1M | 5.4M | 5.1M |
| Profitability Metrics | |||||
| EBITDA | (65.8M) | (22.8M) | (23.5M) | (27.8M) | (20.4M) |
| D&A | 230.4K | 240.0K | 246.0K | 103.0K | 132.4K |
| EBIT | (66.0M) | (23.0M) | (23.8M) | (27.9M) | (20.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026